Icatibant clinical trials
Also written Firazyr and HOE-140.
How each study uses icatibant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 Aug 2011 · FIRAZYR · NDA 022150 (FDA, Drugs@FDA)
- European Union
- 11 Jul 2008 · Firazyr · EMEA/H/C/000899 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 12
Shire (8) · Vanderbilt University Medical Center (4) · Vanderbilt University (2) · University of Edinburgh (2) · QuantumLeap Healthcare Collaborative (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · Sebastian Videla (1)
Often tested with
Tested in the same studies.
Remdesivir (1) · Imatinib (1) · Dexamethasone (1) · Cenicriviroc (1) · Apremilast (1) · Dornase alfa (1) · Celecoxib (1) · Famotidine (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test icatibant, phase 3 first.
- Nov 2026Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorPhase 3 · Vanderbilt University Medical Center
Studies
Open first, then newest update. How each study uses icatibant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 ReceptorActive, not recruitingPhase 3Vanderbilt University Medical CenterNCT05834777Written as Icatibant
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Icatibant
- A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced AngioedemaCompletedPhase 4Nang Kuang Pharmaceutical Co., Ltd.NCT07290855Written as Icatibant Injection (Icanticure®)
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).CompletedPhase 2GCS Ramsay Santé pour l'Enseignement et la RechercheNCT05010876Written as Icatibant Injection
- Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) InfectionCompletedPhase 2Sebastian VidelaNCT04978051Written as Firazyr
- A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary AngioedemaCompletedPhase 3TakedaNCT04654351Written as TAK-667
- EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedPhase 3ShireNCT00997204Written as Icatibant
- A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedPhase 3ShireNCT00912093Written as Icatibant
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedPhase 3ShireNCT00097695Written as Icatibant
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00500656Written as Icatibant
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedPhase 3ShireNCT01919801Written as Icatibant
- A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCompletedPhase 3ShireNCT01386658Written as icatibant
- A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese ParticipantsCompletedPhase 3ShireNCT03888755Written as Icatibant
- Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedPhase 1ShireNCT02045264Written as Icatibant (30 mg)
- Mitochondria and Chronic Kidney DiseaseCompletedPhase 2Vanderbilt University Medical CenterNCT03177798Written as Icatibant
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2WithdrawnPhase 2Vanderbilt University Medical CenterNCT03005184Written as Icatibant
- Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated AngioedemaTerminatedPhase 4Vanderbilt University Medical CenterNCT01574248Written as icatibant
- Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAECompletedPhase 4Massachusetts General HospitalNCT01457430Written as Icatibant
- Bradykinin Receptor Blocker in ACE Inhibitor-associated AngioedemaTerminatedPhase 1Vanderbilt UniversityNCT00517582Written as HOE-140
- Bradykinin Receptor Antagonism During Cardiopulmonary BypassCompletedPhase 2/3Vanderbilt UniversityNCT00223704Written as HOE 140
See all 23 studies that test icatibant →
Given beside what is tested · 1 — icatibant is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with icatibant
Codes
What other systems call icatibant · ClinicalTrials.gg INT003531
- MeSH (NLM) C065679icatibantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7PG89G35Q7ICATIBANTConfirmed FDA, NLM, Wikidata
- RxNorm 1148138Confirmed FDA, Wikidata
- Wikidata Q902379icatibantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98883IcatibantOne source FDA
- DrugBank DB06196One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C065679 | icatibant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7PG89G35Q7 | ICATIBANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1148138 | — | Confirmed FDA, Wikidata |
| Wikidata | Q902379 | icatibant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98883 | Icatibant | One source FDA |
| DrugBank | DB06196 | — | One source Wikidata |
Also registered as icatibant acetate (UNII 325O8467XK · RxNorm 1294605).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.